title: Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model.
abstract: Tumor vaccines have held much promise, but to date have demonstrated little clinical success. This lack of success is conceivably due to poor tumor antigen presentation combined with immuno-suppressive mechanisms exploited by the tumor itself. Knock down of Inhibitor of differentiation protein 2 (Id2-kd) in mouse neuroblastoma whole tumor cells rendered these cells immunogenic. Id2-kd neuroblastoma (Neuro2a) cells (Id2-kd N2a) failed to grow in most immune competent mice and these mice subsequently developed immunity against further wild-type Neuro2a tumor cell challenge. Id2-kd N2a cells grew aggressively in immune-compromised hosts, thereby establishing the immunogenicity of these cells. Therapeutic vaccination with Id2-kd N2a cells alone suppressed tumor growth even in established neuroblastoma tumors and when used in combination with immune checkpoint blockade eradicated large established tumors. Mechanistically, immune cell depletion studies demonstrated that while CD8+ T cells are critical for antitumor immunity, CD4+ T cells are also required to induce a sustained long-lasting helper effect. An increase in number of CD8+ T-cells and enhanced production of interferon gamma (IFNγ) was observed in tumor antigen stimulated splenocytes of vaccinated mice. More importantly, a massive influx of cytotoxic CD8+ T-cells infiltrated the shrinking tumor following combined immunotherapy. These findings show that down regulation of Id2 induced tumor cell immunity and in combination with checkpoint blockade produced a novel, potent, T-cell mediated tumor vaccine strategy.
authors.affiliation: The Joseph E. Robert Jr. Center for Surgical Care and The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center, George Washington University, Washington, District of Columbia, United States of America.
authors.forename: Lina
authors.initials: L
authors.lastname: Chakrabarti
authors.affiliation: The Joseph E. Robert Jr. Center for Surgical Care and The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center, George Washington University, Washington, District of Columbia, United States of America.
authors.forename: Clifford
authors.initials: C
authors.lastname: Morgan
authors.affiliation: The Joseph E. Robert Jr. Center for Surgical Care and The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center, George Washington University, Washington, District of Columbia, United States of America.
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Sandler
mesh_terms: D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007109:Immunity / Q000276:immunology; D007167:Immunotherapy / Q000379:methods; D051797:Inhibitor of Differentiation Protein 2 / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D007371:Interferon-gamma / Q000276:immunology / Q000378:metabolism; D008212:Lymphocyte Depletion / Q000379:methods*; D008815:Mice, Inbred Strains; D008819:Mice, Nude; D016513:Mice, SCID; D009447:Neuroblastoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D034622:RNA Interference / Q000276:immunology*; D000067492:RNAi Therapeutics / Q000379:methods
chemical_list: D019496:Cancer Vaccines; D051797:Inhibitor of Differentiation Protein 2; D007371:Interferon-gamma